Abivax SA Market Cap ($7.92 Billion)
Market Cap & Net Worth: Abivax SA (ABVX)
Abivax SA market cap. Abivax SA (PA:ABVX) has a market capitalization of $7.92 Billion (€6.78 Billion) as of November 6, 2026. Listed on the PA stock exchange, this France-based company holds position #2560 globally and #53 in its home market, demonstrating a -3.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Abivax SA's stock price €77.65 by its total outstanding shares 87253797 (87.25 Million). Also see ABVX cash flow conversion for how efficiently the company converts equity into cash flow.
Abivax SA Market Cap History (2015–2026)
Abivax SA market cap history from 2015 to 2026. Data shows growth from $1.44 Billion to $7.92 Billion (13.79% CAGR). Check ABVX stock price and chart for real-time trading data and today's change.
Index Memberships
Abivax SA is a constituent of 7 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$222.35 Billion | 3.56% | #6 of 119 |
|
CAC Small90
CACS
|
$35.74 Billion | 22.16% | #1 of 64 |
|
CAC All-Tradable
CACT
|
$2.82 Trillion | 0.28% | #51 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.82 Trillion | 0.28% | #51 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.82 Trillion | 0.28% | #51 of 179 |
|
CAC PME
CAPME
|
$38.07 Billion | 20.80% | #2 of 34 |
|
CAC Health Care
FRHC
|
$266.99 Billion | 2.97% | #7 of 36 |
Weight: Abivax SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Abivax SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Abivax SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ABVX net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
63.90x
Abivax SA's market cap is 63.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $642.66 Million | $151.00K | -$14.31 Million | 4256.00x | N/A |
| 2017 | $880.34 Million | $356.00K | -$11.22 Million | 2472.86x | N/A |
| 2018 | $1.21 Billion | $815.00K | -$15.82 Million | 1481.94x | N/A |
| 2019 | $2.30 Billion | $-7.00K | -$30.63 Million | -328614.25x | N/A |
| 2020 | $3.51 Billion | $14.00K | -$37.55 Million | 250650.34x | N/A |
| 2021 | $2.91 Billion | $37.00K | -$42.45 Million | 78712.24x | N/A |
| 2022 | $630.41 Million | $4.58 Million | -$60.74 Million | 137.56x | N/A |
| 2023 | $1.00 Billion | $4.62 Million | -$147.74 Million | 216.78x | N/A |
| 2024 | $689.58 Million | $10.79 Million | -$176.24 Million | 63.90x | N/A |
Competitor Companies of ABVX by Market Capitalization
Companies near Abivax SA in the global market cap rankings as of November 6, 2026. Also see ABVX asset base for a full breakdown of the balance sheet.
Key companies related to Abivax SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #176 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #405 globally with a market cap of $69.48 Billion USD ( AU$98.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #499 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #176 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $542.50 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $902.90 |
| #405 | CSL Ltd | AU:CSL | $69.48 Billion | AU$202.40 |
| #499 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $241.46 |
Market Capitalization of Abivax SA (2015–2026)
Market capitalization of Abivax SA from 2015 to today. Between 2015 and today, Abivax SA's market cap moved from $1.44 Billion to $ 7.92 Billion, with a yearly change of 13.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €7.92 Billion | -35.51% |
| 2025 | €12.28 Billion | +1681.07% |
| 2024 | €689.58 Million | -31.16% |
| 2023 | €1.00 Billion | +58.90% |
| 2022 | €630.41 Million | -78.35% |
| 2021 | €2.91 Billion | -17.01% |
| 2020 | €3.51 Billion | +52.55% |
| 2019 | €2.30 Billion | +90.46% |
| 2018 | €1.21 Billion | +37.20% |
| 2017 | €880.34 Million | +36.98% |
| 2016 | €642.66 Million | -55.48% |
| 2015 | €1.44 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 6th, 2026 the market cap of Abivax SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.92 Billion USD |
| MoneyControl | $7.92 Billion USD |
| MarketWatch | $7.92 Billion USD |
| marketcap.company | $7.92 Billion USD |
| Reuters | $7.92 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials f… Read more